WASHINGTON--(BUSINESS WIRE)-- The Association of Clinical Research Organizations, which represents the global CRO industry, issued the following statement in response to the Government Accountability Office’s report on the Food and Drug Administration’s Overseas Offices.
“The members of ACRO conduct ethical, high-quality clinical research in more than 115 countries,” said Doug Peddicord, Ph.D., Executive Director. “A strong global regulatory regime is imperative to maintain confidence in this important research and the world looks to the U.S. FDA as the leading regulatory authority. For these reasons, ACRO this year has been advocating for increased appropriations for the FDA’s Office of International Programs. Congress must provide the OIP with additional resources so it may carry out its critical role in overseeing foreign clinical trials, as well as its responsibilities to ensure the safety of imported drugs and food.”
The Association of Clinical Research Organizations (ACRO) represents companies whose focus is clinical research. The association provides an active voice for the global CRO industry, which provides specialized services that are integral to the development of drugs, biologics and medical devices. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ approximately 70,000 professionals worldwide and annually conduct more than 9,000 clinical trials involving nearly two million participants in 115 countries. For more information, please visit www.acrohealth.org.
Association of Clinical Research Organizations (ACRO)
John Lewis, 202-464-2310
KEYWORDS: United States North America District of Columbia
INDUSTRY KEYWORDS: Stem Cells Health Biotechnology Clinical Trials Public Policy/Government Healthcare Reform Pharmaceutical Public Policy White House/Federal Government FDA